September 27

The Radoff-Sudbury Group Sets the Record Straight and Highlights Key Facts that Reinforce the Need for Targeted Boardroom Change at LifeVantage Corporation

Retrieved on: 
Thursday, October 19, 2023
Professional Services, Finance, FINRA, Protandim, Farmer, CARD, TSR, Interview, INFO, EPS, Annual general meeting, Farmer Brothers, Consultant, ANY, MLS, Harte Hanks, Vaalco Energy, Foot, September 27, Letter, Jon Radoff, BLUE, NYSE, SEC Rule 10b-5, Platinum, Management, Security (finance), Pharmaceutical industry, Cryptocurrency, Self storage, Property management, Holding company, Financial adviser, Audit, Auction, Shareholder

Since 2020, the Company has seen a 26% decline in consultants, a 16% decline in customers and a 20% decline in active accounts.

Key Points: 
  • Since 2020, the Company has seen a 26% decline in consultants, a 16% decline in customers and a 20% decline in active accounts.
  • These concerning declines underscore the need to install proven operators with direct selling experience in LifeVantage’s boardroom.
  • In fact, we have received unsolicited messages from consultants who have indicated that they hope to see change implemented at the Board-level.
  • LifeVantage fails to acknowledge it is located outside of Salt Lake City while comparing the lease to city rates.

The First Bancorp Declares Third Quarter Dividend

Retrieved on: 
Thursday, September 28, 2023
Banking, Professional Services, Finance, FNLC, First Bancorp, Security (finance), Bank, First National Bank, September 27, Holding company

The First Bancorp (NASDAQ: FNLC), the parent company of First National Bank, today declared a quarterly cash dividend of 35 cents per share.

Key Points: 
  • The First Bancorp (NASDAQ: FNLC), the parent company of First National Bank, today declared a quarterly cash dividend of 35 cents per share.
  • This third quarter dividend is payable October 20, 2023 to shareholders of record as of October 10, 2023.
  • "I'm pleased to announce a third quarter dividend of 35 cents per share", remarked President & Chief Executive Officer, Tony C. McKim.
  • "The quarterly dividend is an important part of the value we offer our shareholders.

Montage Health Prepares for Ohana Opening, a Major Advancement in Youth Mental Health

Retrieved on: 
Thursday, September 7, 2023
Mental Health, Teens, Children, Hospitals, Family, Other Health, Health, Consumer, General Health, Community Hospital of the Monterey Peninsula, Music, NBBJ, September 27, Garden, Hope, Multimedia, School, Monterey Peninsula, Community hospital, MD, Patient, Physical fitness, Mental health, Nursing

Montage Health will celebrate the upcoming fall opening of its long-awaited Ohana campus, a 55,600-square-foot residential and outpatient facility designed to provide mental health care and treatment for youth and their families.

Key Points: 
  • Montage Health will celebrate the upcoming fall opening of its long-awaited Ohana campus, a 55,600-square-foot residential and outpatient facility designed to provide mental health care and treatment for youth and their families.
  • “Youth mental health has been characterized as the public health issue of our time.
  • “Hope is what sustains young people on their journey to build mental health and resilience, and it is what inspires communities to support mental health initiatives.
  • Ohana is ‘Where Hope Grows.’”
    In contrast to conventional mental health facilities, the campus’ innovative design prioritizes curiosity, connection and comfort alongside safety.

Practice Changing Study Highlights Value of Starting Immunotherapy Before Targeted Therapies in Patients with BRAF-Mutated Melanoma

Retrieved on: 
Tuesday, October 4, 2022
DREAM, Nation, Cancer, MEK, Hospital, American Journal of Clinical Oncology, Melanoma, American Cancer Society, Mortality, NCI, Neoplasm, Physician, Ipilimumab, Immunotherapy, Survival, Research, Disease, New Jersey-New York 7 Conference, NCI-designated Cancer Center, Clinical trial, Hackensack Meridian Health, New, Multimedia, Protein, Nursing, BRAF, Patient, Progression-free survival, September 27, View, Annual report, Mutation, Immune system, MedStar Health, CI, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian School of Medicine, Strathcona County, Georgetown, Journal, Oncology, Nivolumab, Education, Aftercare, Diagnosis, MedSTAR, Dabrafenib, III, Pharmaceutical industry, Vaccine

Targeted medications and immunotherapy have become standard care for people with advanced melanoma.

Key Points: 
  • Targeted medications and immunotherapy have become standard care for people with advanced melanoma.
  • Starting in 2015, 265 patients with metastatic melanoma were randomly assigned to one of two groups.
  • One group started treatment with combination ipilimumab and nivolumab immunotherapy, and the second group began with the targeted therapies dabrafenib and trametinib.
  • Two-year overall survival was 72% among patients who received combination immunotherapy first versus 52% for those who took the two targeted therapies as initial treatment.